PR84842

FREMONT, Calif., July 20, 2020, /PRNewswire=KYODO JBN/--

World's first single-use two channel ECG and heart rate biosensor provides 72-

hour patient monitoring with remote data access in ambulatory, hospital and

home settings

LifeSignals Group, today announced USFDA 510(k) clearance has been received for

their LifeSignals ECG Remote Monitoring Patch Platform. The LifeSignals ECG

Remote Monitoring Patch Platform is a wireless remote monitoring system

intended for use by healthcare professionals for the continuous collection of

Electrocardiography (ECG) and Heart Rate monitoring in ambulatory, hospital,

home and healthcare settings. Data is transmitted wirelessly from the

LifeSignals Wireless Medical Biosensor LP1250 to a remote Secure Server for

storage and analysis.

Healthcare professionals can remotely access patient data via third-party

software for the screening and monitoring of common Cardiac Arrhythmias such

Atrial Fibrillation, enabling rapid treatment decisions, independent of patient

location.

"This FDA clearance represents a major step forward in our drive to 'untether'

patient monitoring systems," said Surendar Magar, co-founder and CEO of

LifeSignals. "The interoperable Biosensor gives partners access to a

ready-to-integrate, multi-parameter medical wearable with a straightforward

ecosystem for fast on-boarding. Once in use, it enables remote patient

monitoring services to be expanded rapidly and professionals can make faster

treatment decisions while patients can be confident of receiving data-driven,

personalized therapy."

The LifeSignals Wireless Medical Biosensor LP1250 has several unique features:

- 72-hour data capture of two-channel ECG and Heart Rate data for enhanced

patient diagnosis

- Single use device that reduces infection control concerns and operational

costs

- Lightweight and splash-proof for improved patient comfort and compliance

- Proprietary patented single-chip LC1100 Life Signal Processor platform,

allowing secure capture, storage and transmission of patient data even in

'noisy' multi- patient hospital environments

FDA clearance follows CE marking and HSA approval. The LifeSignals Wireless

Medical Biosensor LP1250 will be sold worldwide as a white-labeled device

through a network of partnerships from OEMs and telehealth software providers

to specialist hospital facilities.

Further information can be found at www.lifesignals.com.

Photo - https://mma.prnewswire.com/media/1216854/Life_Signals_LP1250.jpg

Contacts:

LifeSignals Group

Kim Ramessa

Product Marketing Manager

M: +44 (0) 7425 316305

E: kim.ramessa@lifesignals.com

Media

Richard Hayhurst

RHApr

M: +44 (0) 7711 821527

E: richard@rhapr.eu

SOURCE: Life Signals Inc